samedan logo
 
 
spacer
home > pmps > winter 2021 > a dose of industrial edge for pharmaceutical manufacturing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Dose of Industrial Edge for Pharmaceutical Manufacturing

The pharmaceutical and life science sector has not escaped the effects of the pandemic, with employees working from home and only critical staff and visitors allowed to visit production sites. We’ve been reminded how fragile the world is, and how something we can’t see can wreak havoc on a global scale. The word ‘biologics’ is now commonplace on the world stage, and biologic manufacturers continue to search for a ‘100% vaccine’, which is an illustration of how the community is coming together to accelerate the response. Governed by strict regulations, few other industry sectors can claim they are regulated as stringently. With a vaccine set to be produced on a global scale, by multiple manufacturers who are under enormous pressure to deliver ‘the antidote’, how can they adhere to FDA regulations and comply with GMP in a fast-moving operation? How can their technical partner help them maximise their value chain?

The key drivers within this sector are well affirmed as: time-to-market, quality/regulations, flexibility, and efficiency. The ability to up-scale from clinical trials of small batches to full production, while maintaining quality, is paramount.

Before the COVID-19 pandemic, the Industry 4.0 evolution had already impacted the way pharma adopts new technologies and digitalises its manufacturing plants. The goal was to remain on top of the game by addressing the well-versed industry drivers. These factors have emanated from market forces, such as our demand for new medicines, new entrants into the market, uncertainty, complexity, and cost.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andrew Matthews, Vertical Account Manager, Pharmaceutical and Life Science, at Siemens Digital Industries is helping pharmaceutical and life science organisations embrace digitalisation. Andrew supports the automation of their value chain to get the products from the lab to the patient more swiftly. He currently supports the Institute of Sales Management (ISM) as a mentor and is part of their advisory committee reviewing new members and helping the next generation of sales professionals. He is a keen cyclist and skier.
spacer
Andrew Matthews
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Agilent Joins AMBIC to Advance Biomanufacturing

SANTA CLARA, Calif., April 04, 2022 – Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s commitment to partnering to support the provision of the next generation of analytical tools and comprehensive solutions needed by academic, pharmaceutical, and clinical researchers.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement